Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
STXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.54 - $3.05
Previous CloseN/A
Volume282.58K
Average Volume (3M)515.11K
Market Cap
$255.91M
Enterprise Value$190.51M
Total Cash (Recent Filing)$10.60M
Total Debt (Recent Filing)$5.87M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Nov 06, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding91,071,480
10 Day Avg. Volume321,817
30 Day Avg. Volume515,114
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue6.93
Enterprise Value/Gross Profit12.97
Enterprise Value/Ebitda-7.74
Forecast
1Y Price Target
$4.50Price Target Upside60.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Product AdoptionMagic is now in use in 30% of the company's accounts compared to 20% in Q1, indicating increased adoption and positive physician feedback.
Regulatory ApprovalsThe July US clearance of Magic Sweep is a big regulatory achievement and should be followed by several more key US and EU approvals before year-end.
Revenue GrowthRevenue for Q2 was $8.8M, up 95% from the prior year and up 18% from the prior quarter, beating the Street's $8.1M estimate.
Bears Say
Financial LiquiditySTXS ended the quarter with cash and cash equivalents of $7.0M and no debt, and raised $12.5M via a direct offering, giving a pro forma cash balance of $18.8M.
Product Launch ChallengesGenesisX, Stereotaxis’ mobile robot that can be installed in days rather than months, has launched in Europe and is expected to be FDA cleared soon.
Regulatory MilestonesThe company's planned regulatory milestones and initial commercial launches this year will help support substantial growth in 2026.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.54 and its highest was $3.05 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $255.91M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Nov 06, 2025 which is in 55 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Aug 07, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.065 by $0.015.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.06.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 91,071,480 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.065. Following the earnings report the stock price went up 14.155%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (60.14% Upside)
$4.50 (60.14% Upside)
Blogger Sentiment
Bullish
STXS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.49%
12-Months-Change
Fundamentals
Return on Equity
-198.62%
Trailing 12-Months
Asset Growth
14.32%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. is a leader in the field of robotic-assisted cardiac surgery and electrophysiology. Based in St. Louis, Missouri, the company develops advanced robotic systems and software for the treatment of complex heart conditions. Its flagship product, the Niobe® Robotic Magnetic Navigation System, enables the precise navigation of catheters in the heart, improving the accuracy and safety of procedures such as ablation for arrhythmias. Stereotaxis operates primarily in the medical technology sector and focuses on enhancing patient outcomes through innovation in cardiac care.
STXS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and strategic progress with product launches and FDA clearances. However, ongoing operating losses and administrative challenges in Europe were noted as areas of concern. Overall, the positive developments outweigh the negatives.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$4.50
▲(60.14% Upside)
Technical Analysis
Ownership Overview
21.80% Insiders
6.87% Mutual Funds
30.55% Other Institutional Investors
35.41% Public Companies and
Individual Investors